(WGBS) Launches the ICELL8(TM) Single-Cell System at ASHG

Company Presents Data Further Demonstrating Significant Benefits of ICELL8 Single-Cell System to Single-Cell Researchers

FREMONT, Calif., Oct. 6, 2015  — WaferGen Bio-systems (Nasdaq:WGBS) announced today the commercial launch and presentation of data from the ICELL8™ Single-Cell System at the American Society of Human Genetics (ASHG) annual meeting in Baltimore, MD.

In the hands of world-class early access partners globally, WaferGen’s ICELL8 Single-Cell system has consistently demonstrated the power to isolate thousands of single-cells, the control to identify and process individual cells using CellSelect™ automated imaging and software and the ability to provide critical insight derived from running multiple samples or experiments on a single chip. These revolutionary technology advancements in single-cell analysis have the potential to not only accelerate the drug discovery and development process, but also expand fundamental biological discovery and understanding. WaferGen will present a poster at ASHG highlighting data generated by the Company demonstrating the ICELL8 Single-Cell System’s ability to identify rare cells from a cell population at a sensitivity of <1%. The poster, number 1906W, will be presented at the conference on Wednesday, October 7, from 6-7pm. Additional details will also available at WaferGen’s ASHG booth (number 1027).

Early access partners and collaborators for the ICELL8 Single-Cell System included Genentech, Karolinska Institutet, The University of Texas MD Anderson Cancer Center, National Jewish Health, and The Broad Institute.  Data from a multitude of early access experiments demonstrated that single cells from solid tumors, brains cells, pulmonary airway cells, multiple cell lines, and nuclei, ranging from 5 to 100 µm in size, can be isolated and dispensed into a single chip without pre-selection or filtering.

“We are extremely pleased with the results being generated by our ICELL8 Single-Cell System, including those presented here at ASHG, at recent conferences in Europe and those presented by our early access partners.  As we enter the commercial single-cell market, we are excited by the potential of our technology to enable breakthrough scientific discoveries,” said Rollie Carlson, President and CEO of WaferGen.

About WaferGen

WaferGen Biosystems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The single cell analysis platform is a revolutionary system which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing. The system can also enable processing of up to eight samples by partitioning the chip into 8 sections. The SmartChip platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel single-plex PCR for one-step target enrichment and library preparation for clinical NGS. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage, our expectations regarding our development of future products including single cell analysis technologies and our expectations concerning our competitive position and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: INVESTOR CONTACTS:
         LifeSci Advisors, LLC
         Brian Ritchie
         BRitchie@LifeSciAdvisors.com

         WaferGen Bio-systems, Inc.
         Rollie Carlson
         Rollie.Carlson@wafergen.com